Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

L-TIL Plus Tislelizumab as Second Line Therapy for PD-1 Inhibitor Resistant Advanced NSCLC Patients

NCT05878028 is registered in ClinicalTrials.gov with Quanli Gao as lead sponsor.

NCT NCT05878028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05878028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
L-TIL Plus Tislelizumab as Second Line Therapy for PD-1 Inhibitor Resistant Advanced NSCLC Patients
Lead sponsor
Quanli Gao
Phase
Phase 2
Overall status
Unknown status
Start date
September 16, 2022
Completion date
September 15, 2025
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer